Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters

New Hormonal Contraceptives: A Comprehensive Review of the Literature

“…Forty subjects changed from Papanicolaou smear grade I, IIa, or IIb at baseline to grade IIIa (33) or grade IIIb-IV (7). 22 The authors concluded that these changes were not related to the vaginal ring but were detected because of more frequent screening.…”

“…In a trial involving 130 regularly menstruating women who were not lactating or pregnant, MPA-E 2 was compared with estradiol valerate 5 mg-norethisterone enanthate 50 mg (EV-NE; Mesigyna; Schering, Berlin, Germany), an injectable hormone contraceptive that is not available in the United States (65 women/group). 33 Efficacy, bleeding patterns, and adverse events were assessed. No pregnancies occurred throughout the 6-month trial; however, 23.1% of women treated with MPA-E 2 withdrew for reasons that included amenorrhea (45.5%), headache (18.2%), weight gain (18.2%), and prolonged bleeding plus backaches (9.1%).…”

“…37 No changes in glucose metabolism, insulin secretion, liver function, hemoglobin, hematocrit, or blood pressure occurred with MPA-E 2 . 33,34,37,39,45 Weight gain during clinical trials varied from 0-5 kg. 33,34,37,39 In particular, the weight of women treated with MPA-E 2 increased an average of 0.27 kg/month for the first 7 months of the trial.…”

“…33,34,37,39,45 Weight gain during clinical trials varied from 0-5 kg. 33,34,37,39 In particular, the weight of women treated with MPA-E 2 increased an average of 0.27 kg/month for the first 7 months of the trial. After 1 year, those who initially weighed less than 68.2 kg gained 0.92-1.82 kg, and those weighing more than 68.2 kg gained 1.36-3.64 kg.…”

“…No changes in gynecologic examinations were associated with MPA-E 2 . 28,33 A multicenter trial assessed the effects of MPA-E 2 and NET-EE 7/7/7 on lipid levels. 47 Subjects had no restrictions in diet or alcohol consumption.…”